AVITA Medical Inc (RCEL)

Over the past six months, AVITA Medical's stock price decreased by 5.86% to $4.18 as of May 7, 2026, with a significant decline of 51.79% from May 5, 2025, to May 1, 2026. Shareholder dilution, marked by an 80% increase in shares outstanding, is a major risk. Despite the falling trend, the stock price rose 49% in the 90 days leading up to May 7, 2026. On April 9, 2026, AVITA Medical secured a 10-year BARDA agreement worth up to $25.5 million, which initially inspired a stock rally. Cary Vance was appointed CEO, and Jan Stern Reed was elevated to Chair of the Board on May 1, 2026. The company filed a $200 million S-3 shelf registration to sell stock and warrants on March 31, 2026. The CFO purchased shares on March 11 and February 23, 2026. The company reported its Q3 2025 earnings on November 6, 2025, with an EPS of -$0.46 and revenue of $17.06 million, missing analyst estimates. Analysts generally have a "Buy" consensus rating with an average price target of $7.88, while an AI model assigned a "Sell" rating.

Information detailing the demand seasonality for AVITA Medical's products and services was not available.

AVITA Medical is a therapeutic acute wound care company in the Healthcare sector, focusing on regenerative medicine products for wound healing, particularly for thermal burn and trauma wounds. Its core business is the RECELL System, which produces "Spray-On Skin Cells" from a patient's skin sample. The system is FDA-approved for thermal burn and trauma wounds, full-thickness skin defects, and vitiligo. The company has also introduced RECELL GO, a next-generation system for preparing Spray-On Skin. AVITA Medical's product portfolio includes PermeaDerm, a biosynthetic wound matrix, and Cohealyx, a collagen-based dermal matrix.

AVITA Medical operates in the United States, Japan, the European Union, Australia, and the United Kingdom. The RECELL System has regulatory clearances in Europe, Australia, and Japan, and RECELL GO has CE Mark approval for European markets and certification from Australia's Therapeutic Goods Administration. While the company has product approval in Australia, Canada, and China, its primary focus is the U.S., with growing international sales in Japan.

AVITA Medical's brand reputation can be inferred from FDA approvals for its RECELL System and the BARDA agreement, which are positive indicators. The consensus "Buy" rating from analysts suggests a favorable outlook. However, concerns about stalled revenue growth, declining gross margins, shareholder dilution, and a "Sell" rating from an AI model could negatively impact investor confidence and brand perception.

AVITA Medical has significant institutional ownership, with 76 institutional owners holding 4,929,651 shares. The largest institutional shareholders include Vanguard Group Inc and BlackRock, Inc. Insider sentiment is positive, with insiders purchasing $719.1K worth of shares over the last year.